Lyman et al identified a number of factors that may be associated with a tendency to undertreat a patient with an aggressive non-Hodgkin's lymphoma. A patient who receives low dose chemotherapy is at risk for disease progression that could have been prevented with adequate therapy. The authors are from the University of Washington in Seattle and Duke University in Durham, North Carolina.
• I would imagine that patient who did not receive prophylactic G-CSF would be more likely to develop neutropenia, with chemotherapy held until counts had recovered.
total number of risk factors =
= SUM(points for all 5 factors)
Interpretation:
• minimum score: 0
• maximum score: 5
• The higher the score the more likely a patient will not receive full dose chemotherapy.
To read more or access our algorithms and calculators, please log in or register.
